Edgewise Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Edgewise Therapeutics (NASDAQ:EWTX) reported Q4 earnings with an EPS of $-0.47, missing estimates by 9.3% compared to the expected $-0.43. Revenue remained unchanged from the previous year. This follows a pattern from the last quarter where the company also missed EPS estimates, leading to a 3.67% drop in share price the following day.
February 22, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Edgewise Therapeutics reported a Q4 EPS of $-0.47, missing estimates by 9.3%, with unchanged revenue from the previous year. This follows a previous earnings miss that resulted in a 3.67% stock price drop.
Given the reported earnings miss and the historical context of how the stock reacted to a similar situation last quarter, it's likely that EWTX's stock price will experience a short-term decline. The pattern of missing earnings estimates and the immediate past reaction of a 3.67% drop in stock price the day after the last earnings miss suggest a negative investor sentiment that could repeat.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100